0000000000568195

AUTHOR

S. Beckebaum6

showing 1 related works from this author

Renal Function at Two Years in Liver Transplant Patients Receiving Everolimus: Results of a Randomized, Multicenter Study

2013

In a 24-month prospective, randomized, multicenter, open-label study, de novo liver transplant patients were randomized at 30 days to everolimus (EVR) + Reduced tacrolimus (TAC; n = 245), TAC Control (n = 243) or TAC Elimination (n = 231). Randomization to TAC Elimination was stopped prematurely due to a significantly higher rate of treated biopsy-proven acute rejection (tBPAR). The incidence of the primary efficacy endpoint, composite efficacy failure rate of tBPAR, graft loss or death postrandomization was similar with EVR + Reduced TAC (10.3%) or TAC Control (12.5%) at month 24 (difference -2.2%, 97.5% confidence interval [CI] -8.8%, 4.4%). BPAR was less frequent in the EVR + Reduced TAC…

Graft RejectionMalemTOR inhibitormedicine.medical_treatmentMedizinLiver transplantationKidneylaw.inventionAntineoplastic AgentImmunosuppressive AgentRandomized controlled triallawImmunology and AllergySirolimuPharmacology (medical)Prospective StudiestacrolimusProspective cohort studyglomerular filtration rateIncidenceGraft SurvivalMiddle AgedEuropeEverolimuTreatment OutcomeFemaleImmunosuppressive Agentsmedicine.drugHumanAdultmTOR inhibitorsmedicine.medical_specialtyliver transplantation everolimusRandomizationAdolescentEverolimus glomerular filtration rate mTOR inhibitors renal function tacrolimusUrologyRenal functionAntineoplastic Agentschemical and pharmacologic phenomenaFollow-Up StudieYoung AdultmedicineHumansEverolimusAgedSirolimusTransplantationEverolimusDose-Response Relationship Drugbusiness.industryrenal functiontacrolimuSouth AmericaSurgeryLiver TransplantationTransplantationstomatognathic diseasesProspective StudieSirolimusNorth AmericabusinessFollow-Up Studies
researchProduct